Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...

As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...

A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...

The investigational monoclonal antibody nipocalimab is associated with significant improvement in patients with generalized ...

Truist analyst Srikripa Devarakonda backs away from bullish call as competition mutes potential for biotech’s drug pipeline.

"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...

At the STAT summit, executives discuss their challenges, and hopeful signals, about breaking into markets on obesity and ...

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic ...

Four IPOs each raised at least $75 million this week as the Fall IPO market continued to hum along, while one company ...

Another local biopharmaceutical company has emerged from stealth mode with several million dollars in financing. Tolerance ...